Captor Therapeutics SA
WSE:CTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Captor Therapeutics SA
Other Operating Expenses
Captor Therapeutics SA
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Captor Therapeutics SA
WSE:CTX
|
Other Operating Expenses
zł5.8m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
M
|
Marvipol Development SA
WSE:MVP
|
Other Operating Expenses
zł3.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
M
|
MLP Group SA
WSE:MLG
|
Other Operating Expenses
-zł960k
|
CAGR 3-Years
70%
|
CAGR 5-Years
51%
|
CAGR 10-Years
24%
|
|
|
L
|
Lokum Deweloper SA
WSE:LKD
|
Other Operating Expenses
zł96.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
45%
|
|
|
C
|
CFI Holding SA
WSE:CFI
|
Other Operating Expenses
-zł76.6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
Develia SA
WSE:DVL
|
Other Operating Expenses
-zł237k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
Captor Therapeutics SA
Glance View
Captor Therapeutics SA engages in the development of protein degradation drugs for cancer and autoimmune diseases. The company is headquartered in Wroclaw, Woj. Dolnoslaskie and currently employs 98 full-time employees. The company went IPO on 2021-04-19. The firm works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The firm covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.
See Also
What is Captor Therapeutics SA's Other Operating Expenses?
Other Operating Expenses
5.8m
PLN
Based on the financial report for Dec 31, 2024, Captor Therapeutics SA's Other Operating Expenses amounts to 5.8m PLN.
What is Captor Therapeutics SA's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
-18%
Over the last year, the Other Operating Expenses growth was -18%. The average annual Other Operating Expenses growth rates for Captor Therapeutics SA have been -33% over the past three years , -18% over the past five years .
